TSH Biopharm Corporation Limited (TPEX:8432)

Taiwan · Delayed Price · Currency is TWD

51.10

-0.80 (-1.54%)

Mar 6, 2026, 9:30 AM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Investment	551.28M	313.61M	93.69M	-	-
Investment Growth	75.78%	234.74%	-	-	-
Adjustment and Elimination	-64.07M	-	-	-	-
Domestic Cardiovascular and Gastrointestinal Drugs	628.51M	497.31M	647.38M	413.48M	447.86M
Domestic Cardiovascular and Gastrointestinal Drugs Growth	26.38%	-23.18%	56.57%	-7.68%	-11.78%
Total	1.12B	810.92M	741.07M	413.48M	447.86M
Total Growth	37.59%	9.43%	79.23%	-7.68%	-11.78%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Taiwan	1.12B	810.92M	741.07M	413.48M	447.86M
Taiwan Growth	37.59%	9.43%	79.23%	-7.68%	-11.78%
Total	1.12B	810.92M	741.07M	413.48M	447.86M
Total Growth	37.59%	9.43%	79.23%	-7.68%	-11.78%

Source: S&P Global Market Intelligence.